Zipalertinib (CLN-081)

Name: Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Special populations
Published: 2026-09-14T15:39:06-04:00

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417

Manufacturer: Taiho Oncology
Regulatory submission: NDA submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Special populations

1 evidence topic · 1 source

Trial eligibility: organ function

“Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values.” (opens the source at this quote in a new tab)

Renal and hepatic dose adjustments

No evidence found.